MARVEL-TTAS

JRCT ID: jRCTs071180059

Registered date:19/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Deep vein thrombosis
• Date of first enrollment: 30/09/2019
• Target sample size: 120
• Study type: Interventional
• Intervention(s): Administer 20mg/day apixaban (20mg/day) for 7days and 10mg/day apixaban following days as antithrombotic therapy for patients with deep vein thrombosis.

Outcome(s)

• Primary Outcome: Fluctuation of AR10-AU C30 value with or without bleeding events

Secondary Outcome

1) Fluctuation of AR10-AUC30 value in the case of venous thromboembolism

2) Fluctuation of AR10-AUC30 value after the remission venous thromboembolism

3) All death

4) Other adverse events

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: New onset case of venous thromboembolism and deep vein thrombosis, who requires permanent antithrombotic therapy

Exclude criteria

1. contraindication of apixaban usage
2. Patients who are already taking antithrombotic or thrombolytic therapies
3. Patients who are judged as an inappropriate case to enroll

Related Information

• Primary Sponsor: Tsujita Kenichi
• Secondary Sponsor: Arima Yuichiro
• Source(s) of Monetary Support: Bristol-Myers Squibb